Non-interventional study comparing treatment satisfaction in patients treated with antihistamines

Clinical Drug Investigation

Volumn 28, Issue 4, 2008, Pages 221-230

  De Vos, Christine ^a,c   Mitchev, Krassimir ^a   Pinelli, Marie Etienne ^a   Derde, Marie Paule ^b   Boev, Rossen ^c  

^a UCB PHARMA   (Belgium)

^b Veeda Clinical Research SA   (Belgium)

^c Veeda Clinical Research SA ^*  (Belgium)

Author keywords

Allergic rhinitis; Antihistamines, therapeutic use; Cetirizine, therapeutic use; Desloratadine, therapeutic use; Ebastine, therapeutic use; Fexofenadine, therapeutic use; Levocetirizine, therapeutic use; Loratadine, therapeutic use; Urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; LEVOCETIRIZINE; LORATADINE;

ADOLESCENT; ADULT; AGED; ALLERGIC DISEASE; ALLERGIC RHINITIS; ARTICLE; CHILD; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SOMNOLENCE; URTICARIA; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CETIRIZINE; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INFANT; MALE; MIDDLE AGED; PATIENT SATISFACTION; PIPERAZINES; PREVALENCE; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME; URTICARIA;

EID: 40949138937     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828040-00003     Document Type: Article

References (31)

1. ISAAC. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998 Apr 25; 351 (9111): 1225-32
2. Mosges R, Klimek L. Today's allergic rhinitis patients are different: new factors that may play a role. Allergy 2007: 62: 969-75
3. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007: 62: 1057-63
4. Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005 Mar; 84 (3): 163-8
5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic Rhinitis and its Impact on Asthma (ARIA). J Allergy Clin Immunol 2001 Nov; 108 (5 Suppl.): S147-334
6. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998 Apr; 138 (4): 635-8
7. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005: 60: 882-7
8. Grattan CEH, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002;46: 645-57
9. Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006 Feb; 30 (1): 47-51
10. Pfaar O, Wrede H, Barth C, et al. Levocetirizine in patients with chronic idiopathic urticaria: results of a multicenter clinical practice study. Int J Clin Pharmacol Ther 2006 Apr; 44 (4): 191-2
11. Schoenwetter WF, Dupclay Jr L, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004 Mar; 20 (3): 305-17
12. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999 Jul-Aug; 20 (4): 209-13
13. Burge HA, Rogers CA. Outdoor allergens. Environ Health Perspect 2000 Aug; 108 Suppl. 4: 653-9
14. Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Manag Care 2000 Jan; 6 (1 Suppl.): S3-15; quiz S19-20
15. Day JH, Horak F, Briscoe MP, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006; 6: 31-59
16. Bousquet J, Lund VJ, van Cauwenberge P, et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003 Aug; 58: 733-41
17. Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004 Nov-Dec; 3 (6): 632-9
18. Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 Sep; 33: 1305-24
19. Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol Allergy Clin North Am 2005 May; 25: 263-81
20. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005 Mar; 60: 350-3
21. Demoly P, Allaert FA, Lecasble M, et al. Validation of the classification of ARIA (Allergic Rhinitis and its Impact on Asthma). Allergy 2003 Jul; 58: 672-5
22. Yates C. Parameters for the treatment of urticaria and angioedema. J Am Acad Nurse Pract 2002 Nov; 14 (11): 478-83
23. Kozel MA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64 (22): 2515-36
24. Jorissen M, Bertrand B, Stiels B, et al. Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT 2006; 2: 55-62
25. Klimek L, Hundorf I. Levocetirizine in allergic diseases: an open multicentre practice study of efficacy and tolerability. Allergologie 2002; 25: S1-7
26. Klimek L, Wrede H, Schott BC, et al. Patients' perception of the value of levocetirizine in allergic diseases: a multicentre observational study in Germany. Clin Drug Investig 2005; 25 (9): 609-14
27. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006 Apr; 45: 469-74
28. Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2004 Jan; 56: 50-7
29. Grant JA, Riethuisen JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002 Feb; 88 (2): 190-7
30. Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003 Oct; 56 (4): 388-94
31. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 Oct; 114 (4): 838-44